For renal impairment, although most GLP-1 agents have minimal renal clearance, impaired kidney function increases the risk of adverse events such as dehydration from vomiting or decreased drug clearance in polypharmacy
Enzymatic degradation in the digestive tract substantially reduces bioavailability, often to the point where clinical benefits become questionable
Clinical Considerations and Future Research Despite encouraging signals, more research is needed to clarify how GLP-1 therapy influences male fertility and reproductive outcomes
Disclose use to your GP or pharmacist without delay, and seek urgent medical attention via NHS 111 or 999 if you experience severe abdominal pain, persistent vomiting, dehydration, or symptoms of low blood sugar
Revisit the case: WBUR reporter Ally Jarmanning dove into the nuances of this gruesome national network in "Last Seen: Postmortem." Listen to the full podcast here
Although conventional hypoglycemic agents effectively control blood glucose levels, they inadequately prevent major adverse cardiovascular events, such as myocardial infarction and stroke